Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini
Go back to Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini| COGENT (NASDAQ: COGT) | Delayed: 33.10 +0.48 (1.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.62 | 52 Week High | $5.57 | |||
| Open | $32.58 | 52 Week Low | $2.90 | |||
| Day High | $33.53 | P/E | 150.45 | |||
| Day Low | $32.33 | EPS | $0.22 | |||
| Volume | 1,480,114 | |||||
